newsfilter
← Latest News
GlobeNewswire·

BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics

SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in